Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 9/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | CD44 | P16070 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30899242 | 0.85 | HTR2C (0.48) | PNMTHTR2AHTR2CHTR2B | |
| SCHEMBL30014809 | 0.83 | CD44 (0.40) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL16402066 | 0.83 | CD44 (0.40) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL19684582 | 0.82 | PNMT (0.44) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL19711548 | 0.82 | PNMT (0.44) | PNMTADRA2AADRA2BADRA2CCD44 | |
| SCHEMBL19667270 | 0.82 | ADCY6 (0.45) | PNMTADRA2AADRA2BADRA2CCD44 | |
| SCHEMBL31159009 | 0.80 | HTR2C (0.30) | HTR2CMAOB | |
| SCHEMBL25095628 | 0.80 | PNMT (0.46) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL19406882 | 0.80 | PNMT (0.46) | PNMTADRA2AADRA2BADRA2CHTR2A | |
| SCHEMBL17462463 | 0.80 | PNMT (0.50) | PNMTADRA2AADRA2BADRA2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612131-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| WO-2024095003-A1 | NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2024-05-10 | — | — | WO | disclosed |
| CN-117751104-A | Compound with kinase inhibition function and preparation and application thereof | 轶诺(浙江)药业有限公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2022253328-A1 | COMPOUND HAVING KINASE INHIBITORY FUNCTION, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 轶诺(浙江)药业有限公司 | 2022-12-08 | — | — | WO | disclosed |
| CN-115433161-A | Novel HPK1 inhibitor and preparation method and application thereof | 轶诺(浙江)药业有限公司 | 2022-12-06 | — | — | CN | disclosed |
| EP-2603500-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F.HOFFMANN-LA ROCHE AG (CH) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012020008-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | WO | disclosed |